CClinicalTrials.gg
CompletedNCT03084068Updated Dec 18, 2019

Use of Human Dehydrated Umbilical Cord Allograft in Supraspinatus Tendon Repair

An interventional study of Human dehydrated umbilical cord allograft and Placebo in Shoulder Injury, Shoulder Sprain and Supraspinatus Tear, sponsored by MiMedx Group, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-18.

Sponsored by MiMedx Group, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To determine the effectiveness of human dehydrated umbilical cord allograft in standard open rotator cuff repair as assessed by the American Shoulder and Elbow Surgeons (ASES) score 12 months post-op.

02

Conditions studied

  • Shoulder Injury
  • Shoulder Sprain
  • Supraspinatus Tear

Browse trials for

03

In context

Shoulder Injuries

114 studies on the registry are indexed under Shoulder Injuries; 31 are open to participants now.

This study's enrollment of 25 is below the median of 55 across 65 interventional studies indexed under Shoulder Injuries.

Browse Shoulder Injuries studies →

Lead sponsor

MiMedx Group, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. MRI confirmed diagnosis of a full thickness supraspinatus tendon tear necessitating surgical intervention (rotator cuff repair)
  2. Subject is male or female age 18 or older
  3. Subject is willing and able to provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study

Exclusion criteria

Exclusion Criteria:

Subjects who meet ANY of the following criteria will be excluded from the study:

  1. Shoulder pain primarily attributed to any of the following:

    1. Ligament rupture due to use of fluoroquinolones
    2. Capsular tear
    3. Fracture of the humeral head
    4. Inflammation of the joint or surrounding tissue (i.e. osteoarthritis, bursitis)
    5. Neuropathic, radiating pain from conditions resulting in damage or inflammation of the nerve
    6. Previous history of autoimmune connective tissue disorders (i.e. rheumatoid arthritis, systemic lupus erythematosus)
  2. Known history of poor compliance with medical treatments
  3. Subject has bilateral supraspinatus tendon tear
  4. Subject has signs and symptoms of an active infection of the shoulder joint
  5. Retraction of the supraspinatus tendon exceeding 1.5 cm in length
  6. Subject has additional injuries requiring further surgical intervention to the ipsilateral arm
  7. Subject has had previous surgery in the target arm within the past 6 months prior to treatment or plans to have surgery other than Rotator Cuff Repair in the target arm within 180 days of treatment
  8. Subjects currently receiving radiation therapy or chemotherapy
  9. Subjects has used an investigational drug, device or biologic within 12 weeks prior to treatment
  10. Subjects who are pregnant at enrollment or are planning to become pregnant within 180 days of treatment
  11. Subject has any significant medical condition(s) that, in the opinion of the Investigator, would interfere with protocol evaluation and participation
  12. Allergy or known sensitivity to aminoglycoside antibiotics such as gentamicin sulfate and/or streptomycin sulfate
  13. Workers' compensation patients
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Human umbilical cord allograft

    Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft

    Other: Human dehydrated umbilical cord allograft

  • Placebo comparator
    Placebo Control

    Open Rotator Cuff Repair with standard suture repair

    Other: Placebo

Interventions

  • OtherHuman dehydrated umbilical cord allograft

    human dehydrated umbilical cord allograft

  • OtherPlacebo

    Open rotator cuff surgery with standard suture repair

06

What researchers measure

Primary outcomes

  1. ASES score

    The primary endpoint of the study is the number of subjects achieving a 20% increase from baseline in the overall ASES score at 12 months post-op.

    Time frame: 12 months

Secondary outcomes

  1. Constant Murley Score

    Comparison of Constant scores between the two groups at each study time point

    Time frame: 12 months

  2. Shoulder range of motion

    Assessment of the change in the range of motion of the shoulder joint for both treatment groups at each study time point.

    Time frame: 12 months

  3. VAS Pain scores

    Change in patient reported pain from baseline

    Time frame: 12 months

  4. Incidence of tendon re-tear

    Incidence of supraspinatus tendon re-tear in the two treatment groups as assessed by review of MRI scans by independent radiologists

    Time frame: 12 months

  5. Incidence of adverse events

    Incidence of adverse events

    Time frame: 12 months

07

Study locations

1 site
  • Hand & UpperEx Center
    Wexford, Pennsylvania 15090, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03084068
Lead sponsor
MiMedx Group, Inc.
Responsible party
Sponsor
First posted
Mar 20, 2017
Start date
Feb 1, 2017
Primary completion
Jan 17, 2019
Completion
Jan 17, 2019
Last update
Dec 18, 2019

Study contacts

David Mason, MD
study director · MiMedx Group, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion